🩺 Health🌍 World🦠Coronavirus

US says COVID-19 vaccine to start arriving in states Monday

أولى الدفعات من لقاح فايزر- بايونتيك تصل الإثنين إلى مراكز التلقيح في الولايات المتحدة


WASHINGTON: U.S. officials say the nation’s first COVID-19 vaccine will begin arriving in states Monday morning.

Army Gen. Gustave F. Perna said Saturday that shipping companies UPS and FedEx will deliver Pfizer’s vaccine to nearly 150 state locations. Another 450 sites will get the vaccine on Tuesday and Wednesday.

Perna is with Operation Warp Speed, the Trump administration’s vaccine development program. He says the vaccine was timed to arrive Monday morning so that health workers would be available to receive the shots and begin giving them.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.

WASHINGTON (AP) – The U.S. gave the final go-ahead Friday to the nation’s first COVID-19 vaccine, marking what could be the beginning of the end of an outbreak that has killed nearly 300,000 Americans.

Shots for health workers and nursing home residents are expected to begin in the coming days after the Food and Drug Administration authorized an emergency rollout of what promises to be a strongly protective vaccine from Pfizer Inc. and its German partner BioNTech.

Initial doses are scarce and rationed as the U.S. joins Britain and several other countries in scrambling to vaccinate as many people as possible ahead of a long, grim winter. It will take months of work to tamp down the coronavirus that has surged to catastrophic levels in recent weeks and already claimed 1.5 million lives globally.

While the FDA decision came only after public review of data from a huge ongoing study, it has also been dogged by intense political pressure from the Trump administration, which has accused the agency of being too slow and even threatened to remove FDA chief Stephen Hahn if a ruling did not come Friday.

The move sets off what will be the largest vaccination campaign in U.S. history — but it also has global ramifications because it’s a role model to many other countries facing the same decision.
It offers the ability “in this situation where the pandemic is out of control, to bring hope to the people,” Dr. Ugur Sahin, CEO of BioNTech, told The Associated Press.

The world desperately needs multiple vaccines for enough to go around, and the Pfizer-BioNTech shot is the first based on rigorous scientific testing to emerge from that worldwide race — a record-setting scientific achievement that shaved years off the usual process.

“I don’t think you would have found a scientist on this planet that would have predicted this 11 months ago,” said Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia who advises the FDA.

The U.S. is considering a second vaccine, made by Moderna Inc., that could roll out in another week. In early January, Johnson & Johnson expects to learn if its vaccine is working in final testing.

Europe is set to make its own decision on the Pfizer-BioNTech and Moderna shots later this month, an important step as some other candidates that multiple countries were anxiously awaiting have hit roadblocks. Friday, Sanofi and GSK announced a months-long delay after early tests showed their vaccine didn’t work well enough in older adults.

And China and Russia didn’t wait for final-stage tests before beginning vaccinations with some homegrown shots.

President Donald Trump said late Friday that Pfizer had “passed the gold standard of safety,” in a video statement hailing the vaccine as “one of the greatest scientific accomplishments in history.”

About 3 million doses of the vaccine are expected in the first shipments around the country, according to officials with Operation Warp Speed, the Trump administration’s vaccine development program. A similar amount is to be held in reserve for those recipients’ second dose.

The government still is hammering out final recommendations, but expected to follow health workers and nursing homes are other essential workers, older adults and people at high risk because of other health problems. U.S. authorities don’t expect enough for the general population before spring, and that’s assuming there are no manufacturing glitches.

“We would need at least until March, April, to have an impact on the pandemic,” Sahin said. But he predicted that protecting the most vulnerable could start putting a dent in hospitals and deaths sooner.

In a still unfinished study of nearly 44,000 people, the FDA found the vaccine was safe and more than 90% effective across recipients of different ages, including older adults, races and those with health problems that put them at high risk from the coronavirus. It’s authorized for people age 16 and up.


Emergency use means the vaccine still is experimental. Most important for would-be recipients to know:

-Some protection begins after the first dose, but it takes a second dose three weeks later for full protection. It’s unclear how long protection lasts.

-The vaccine protects against COVID-19 illness, but no one yet knows if it can stop the silent, symptomless spread that accounts for roughly half of all cases. The ongoing study will attempt to answer that but for now, the vaccinated still will need to wear a mask and keep their distance.

-Expect a sore arm and some flu-like symptoms such as fever, fatigue, headache and chills after the second dose. While uncomfortable, those reactions only last about a day. “That’s just your immune system working. It’s a good thing,” Offit said.

-Authorities are investigating several allergic reactions reported in Britain by health workers with a history of severe allergies. The FDA said people must have treatments for allergic reactions on hand before they are administered the COVID-19 vaccine, and not give it to those with a known history of severe allergic reactions to any of its ingredients.

-Every vaccine recipient must be given an FDA-written fact sheet about the vaccine and its known risks and benefits.

-FDA didn’t forbid the vaccine’s use in pregnant women but noted there isn’t enough evidence to determine its safety in that group.

If emergency use of Moderna’s vaccine also is authorized, the U.S. expects to vaccinate 20 million people by the end of December. They hope to have enough for another 30 million people in January and 50 million in February.

Globally, Sahin said production should scale up considerably in February, with the companies projecting 120 million to 130 million doses a month to reach 1.3 billion doses in 2021.

Getting shots into arms is the big challenge, especially as a new poll from The Associated Press-NORC Center for Public Affairs Research found only half of Americans want the vaccine when it’s their turn. About a quarter say they won’t get it and the rest aren’t sure.

Political interference has complicated health authorities’ message that the testing was rigorous and cut no corners.

Trump bashed the FDA, again, Friday for taking too long, complaining that the agency “is still a big, old slow turtle.” One of his deputies even pressed Hahn to clear the shots by the end of the day or face possible firing, two administration officials said.

The FDA is unique in analyzing drugmakers’ raw data, a process that takes longer than many other countries’ regulatory reviews. In addition, the FDA insisted that large COVID-19 vaccine studies track at least half the participants for two months to look for side effects, a time period when historically any vaccine problems appear.

 (أ ف ب) :

واشنطن: تصل صباح الإثنين أولى الدفعات من لقاح فايزر/بايونتيك المضاد لكوفيد-19 الذي أعطي الجمعة الضوء الأخضر في الولايات المتحدة، إلى مراكز التلقيح التي ستباشر فورا بإعطاء اللقاح للأميركيين.

والسبت قال الجنرال غاس بيرنا من عملية “وارب سبيد” التي أطلقتها الحكومة الأميركية لضمان تسليم اللقاح ضد كوفيد-19 “بدأت عمليات التوزيع” وستصل “الشحنات الأولى صباح الاثنين”.

وكان الرئيس الأميركي المنتهية ولايته دونالد ترامب قد أكد مساء الجمعة عقب الموافقة الطارئة من السلطات الصحية على استخدام لقاح فايزر/بايونتيك، أن الجرعات الأولى من اللقاح ستقدم في غضون 24 ساعة، أي يوم السبت.

لكن شركة فايزر قالت إن الدفعات الأولى لن تنطلق من مصنعها في ميشيغن إلى مراكز شحن شركتي “يو بي اس” و”فيديكس” المكلّفتين التوزيع، قبل يوم الأحد.

وأوضح الجنرال بيرنا عن هذه المرحلة الأولى من حملة التلقيح التي ستشمل حوالى ثلاثة ملايين شخص “يمكننا أن نتوقع تلقي 145 موقعا في الولايات اللقاح الاثنين، و425 موقعا إضافيا الثلاثاء. والمواقع الـ66 الأخيرة ستتلقى اللقاح الأربعاء”.

ولفت إلى أنه لم يتم “تجهيز أي دفعة من اللقاحات” قبل الحصول على الضوء الأخضر من وكالة الأدوية الأميركية مساء الجمعة.

وأوصت مراكز مكافحة الأمراض والوقاية منها ببدء إعطاء اللقاح لنزلاء دور رعاية المسنين (ثلاثة ملايين شخص) ولموظفي القطاع الصحي (21 مليونا). ومن المفترض أن تتّبع غالبية الولايات توصيات هذه الهيئة.

– لا ضغوط خارجية – الولايات المتحدة هي الدولة الأكثر تسجيلا للوفيات والإصابات بكوفيد-19 مع 295 ألف وفاة وأكثر من 15 مليون إصابة. ومؤخرا تسجّل البلاد أرقاما قياسية على صعيد الإصابات اليومية التي تتخطى المئتي ألف والوفيات اليومية التي تتراوح بين ألفين وخمسمئة وثلاثة آلاف حالة.

وطلبت الحكومة الأميركية مسبقا مئة مليون جرعة من لقاح فايزر/بايونتيك الذي تبلغ نسبة فاعليته 95 بالمئة، أي أنه يخفّض بنسبة 95 بالمئة مخاطر الإصابة بكوفيد-19. وسبق أن أعطت بريطانيا وكندا والمكسيك والبحرين الضوء الأخضر لاستخدام اللقاح.

وكان ترامب قد مارس الجمعة ضغوطا على هيئة الأغذية والأدوية الأميركية “إف دي إيه” التي وصفها بأنها “سلحفاة كبيرة بطيئة الحركة”، وقد حضّها في تغريدة على إعطاء الضوء الأخضر “للقاح اللعين الآن”.

وأفادت صحيفة واشنطن بوست أن البيت الأبيض أمَرَ رئيس هيئة الأغذية والأدوية الأميركية ستيفن هان بإجازة لقاح فايزر-بايونتيك، في اليوم نفسه، أي يوم الجمعة، أو أن يُقدّم استقالته.

ووافقت هيئة الأغذية والأدوية الأميركية على استخدام اللقاح مساء الجمعة.

والسبت أكد هان في مؤتمر عبر الإنترنت “لقد عملنا سريعا نظرا لحالة الطوارئ التي تشكّلها هذه الجائحة، وليس بسبب ضغط خارجي ما”.

وأوضحت الهيئة ماهية حالات الحساسية التي تنصح بعدم تلقي المصابين بها اللقاح، وذلك بعد تسجيل حالتي حساسية خطيرة للقاح في المملكة المتحدة هذا الأسبوع.

وقال المسؤول في الهيئة بيتر ماركس إن ردود فعل كتلك “لم ترد في بيانات التجارب السريرية الواسعة النطاق”، و”سنواصل مراقبتها عن كثب”.

وأوضح أن توصيات عدم إعطاء اللقاح ستشمل فقط المرضى الذين سبق ان أصيبوا “بعوارض حساسية خطيرة” لمكوناته أو للقاحات مماثلة، وليس الأشخاص الذين يعانون من عوارض حساسية خطيرة بالمطلق.

وأوضح أن “نحو 1,6 بالمئة من السكان سبق أن أظهروا عوارض حساسية حادة جراء أطعمة أو على صلة بالأحوال المناخية. لا نريد ان يحرم هذا القدر من الأشخاص من اللقاح”.

وتابع أن الأشخاص الذين لم يظهروا عوارض حساسية خطيرة للقاح أو لأحد مكوناته يمكنهم أن يتلقوه.

Like Love Haha Wow Sad Angry
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Subscribe to our mailing list

* indicates required
Email Format